tiprankstipranks
Advertisement
Advertisement

OPHLF Stock Latest News

Ono’s New GIST Study Puts Early‑Stage Oncology Back in Focus for OPHLF Investors
Company AnnouncementsOno’s New GIST Study Puts Early‑Stage Oncology Back in Focus for OPHLF Investors
6d ago
OPHLF
Ono Pharma’s ONO-1110 Pain Trial Reaches Completion, Setting Up a Key Readout
PremiumCompany Announcements
Ono Pharma’s ONO-1110 Pain Trial Reaches Completion, Setting Up a Key Readout
11d ago
OPHLF
ONO-1110 Depression Trial Completion: What It Means for OPHLF Investors
PremiumCompany Announcements
ONO-1110 Depression Trial Completion: What It Means for OPHLF Investors
18d ago
OPHLF
ONO’s ONO‑1110 Trial Completion Puts Social Anxiety Bet in Investor Focus
PremiumCompany Announcements
ONO’s ONO‑1110 Trial Completion Puts Social Anxiety Bet in Investor Focus
18d ago
OPHLF
ONO’s Tirabrutinib Liver Study Completion: What It Means for OPHLF Investors
PremiumCompany Announcements
ONO’s Tirabrutinib Liver Study Completion: What It Means for OPHLF Investors
30d ago
OPHLF
Real-World Data on Nivolumab Plus Chemo in Japanese Gastric Cancer: What Investors Should Watch
PremiumCompany AnnouncementsReal-World Data on Nivolumab Plus Chemo in Japanese Gastric Cancer: What Investors Should Watch
1M ago
BMY
Ono’s ONO-4578 Breast Cancer Combo Clears Phase I Milestone, Setting Up the Next Investor Catalyst
Premium
Company Announcements
Ono’s ONO-4578 Breast Cancer Combo Clears Phase I Milestone, Setting Up the Next Investor Catalyst
2M ago
OPHLF
ONO’s ONO-7018 Trial Termination: What It Means for OPHLF Investors
Premium
Company Announcements
ONO’s ONO-7018 Trial Termination: What It Means for OPHLF Investors
2M ago
OPHLF
Ono’s Real-World Tirabrutinib Study in Taiwan Reaches Completion, Setting Up a New Catalyst for OPHLF
PremiumCompany Announcements
Ono’s Real-World Tirabrutinib Study in Taiwan Reaches Completion, Setting Up a New Catalyst for OPHLF
2M ago
OPHLF
Ono’s Phase 3 Sapablursen Trial Targets Polycythemia Vera Upside for OPHLF Investors
PremiumCompany Announcements
Ono’s Phase 3 Sapablursen Trial Targets Polycythemia Vera Upside for OPHLF Investors
3M ago
OPHLF
ONO Pharmaceutical Details FY2025 Results and FY2026 Outlook with Focus on Pipeline and Core Metrics
PremiumCompany Announcements
ONO Pharmaceutical Details FY2025 Results and FY2026 Outlook with Focus on Pipeline and Core Metrics
3M ago
Ono Pharmaceutical Delivers Strong FY 2025 Profits but Guides for Lower Revenue in FY 2026
PremiumCompany Announcements
Ono Pharmaceutical Delivers Strong FY 2025 Profits but Guides for Lower Revenue in FY 2026
3M ago
Is OPHLF a Buy, Before Earnings?
PremiumPre-EarningsIs OPHLF a Buy, Before Earnings?
3M ago
ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso
Premium
Company Announcements
ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso
4M ago
OPHLF
ONO Pharmaceutical Posts Strong Profit Growth in Q3 FY2025 and Maintains Full-Year Outlook
Premium
Company Announcements
ONO Pharmaceutical Posts Strong Profit Growth in Q3 FY2025 and Maintains Full-Year Outlook
6M ago
OPHLF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
OPHLF Earnings this Week: How Will it Perform?
6M ago
ONO Pharmaceutical Reports Strong Q2 Financial Performance with Revenue Growth
PremiumCompany Announcements
ONO Pharmaceutical Reports Strong Q2 Financial Performance with Revenue Growth
9M ago
Ono Pharmaceutical’s Tirabrutinib Study: Key Insights for Investors
PremiumCompany Announcements
Ono Pharmaceutical’s Tirabrutinib Study: Key Insights for Investors
9M ago
OPHLF
Ono Pharmaceutical’s Phase 3 Trial: A New Hope for PCNSL Treatment
PremiumCompany Announcements
Ono Pharmaceutical’s Phase 3 Trial: A New Hope for PCNSL Treatment
9M ago
OPHLF
Ono Pharmaceutical’s ONO-1110: A Promising Study for Interstitial Cystitis
PremiumCompany AnnouncementsOno Pharmaceutical’s ONO-1110: A Promising Study for Interstitial Cystitis
9M ago
OPHLF
ONO Pharmaceutical Advances Fibromyalgia Treatment with ONO-1110 Study
Premium
Company Announcements
ONO Pharmaceutical Advances Fibromyalgia Treatment with ONO-1110 Study
9M ago
OPHLF
Ono Pharmaceutical’s ONO-4538 Study: A Potential Game-Changer for Richter’s Transformation
Premium
Company Announcements
Ono Pharmaceutical’s ONO-4538 Study: A Potential Game-Changer for Richter’s Transformation
9M ago
OPHLF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >